Cargando…

Iguratimod represses B cell terminal differentiation linked with the inhibition of PKC/EGR1 axis

BACKGROUND: This study aimed to explore the molecular mechanism and clinical relevance of iguratimod in the regulation of human B cell terminal differentiation. METHODS: An in vitro human antibody-secreting cell (ASC) differentiation system was established to test the effect of iguratimod. B cell ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Yan, Liu, Mei, Tang, Longhai, Du, Fang, Liu, Yuanhua, Hao, Pei, Fu, Qiong, Guo, Qiang, Yan, Qingran, Zhang, Xiaoming, Bao, Chunde
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458835/ https://www.ncbi.nlm.nih.gov/pubmed/30971291 http://dx.doi.org/10.1186/s13075-019-1874-2

Ejemplares similares

Prevention of Immune Nephritis by the Small Molecular Weight Immunomodulator Iguratimod in MRL/lpr Mice
por: Yan, Qingran, et al.
Publicado: (2014)

Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study
por: Kang, Yuening, et al.
Publicado: (2020)

Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study
por: Yan, Qingran, et al.
Publicado: (2023)

Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression
por: Shen, Lichong, et al.
Publicado: (2023)

Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer
por: Yan, Qingran, et al.
Publicado: (2023)

Iguratimod efficacy in palindromic rheumatism treatment
por: Yuan, Fangfang, et al.
Publicado: (2023)

Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study)
por: Yan, Qingran, et al.
Publicado: (2021)

Targeting miR-155 to Treat Experimental Scleroderma
por: Yan, Qingran, et al.
Publicado: (2016)

Corrigendum: Targeting miR-155 to Treat Experimental Scleroderma
por: Yan, Qingran, et al.
Publicado: (2016)

Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
por: Li, Jiangtao, et al.
Publicado: (2013)

Preparation of a Major Metabolite of Iguratimod and Simultaneous Assay of Iguratimod and Its Metabolite by HPLC in Rat Plasma
por: Han, Jun-ping, et al.
Publicado: (2019)

Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology
por: Li, Jie, et al.
Publicado: (2019)

Iguratimod alleviates tubulo-interstitial injury in mice with lupus
por: Xue, Leixi, et al.
Publicado: (2022)

Iguratimod Inhibits the Aggressiveness of Rheumatoid Fibroblast-Like Synoviocytes
por: Lin, Jin, et al.
Publicado: (2019)

Allergic Skin Rash Caused by Iguratimod: A Report of Two Cases
por: Lu, Wentian, et al.
Publicado: (2022)

Randomised, Double-Blind, Placebo-Controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis
por: Li, Yan, et al.
Publicado: (2021)

Effects of iguratimod on inflammatory factors and apoptosis of submandibular gland epithelial cells in NOD mice
por: Wang, Shuying, et al.
Publicado: (2023)

Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
por: Xie, Sisi, et al.
Publicado: (2020)

Investigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis
por: Zeng, Huiqiong, et al.
Publicado: (2022)

EGR1 Promotes Ovarian Hyperstimulation Syndrome Through Upregulation of SOX9 Expression
por: Wang, Huihui, et al.
Publicado: (2023)

Corrigendum: Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape
por: Xie, Sisi, et al.
Publicado: (2020)

Iguratimod Restrains Circulating Follicular Helper T Cell Function by Inhibiting Glucose Metabolism via Hif1α-HK2 Axis in Rheumatoid Arthritis
por: Bai, Ziran, et al.
Publicado: (2022)

Gfi1-Mediated Repression of c-Fos, Egr-1 and Egr-2, and Inhibition of ERK1/2 Signaling Contribute to the Role of Gfi1 in Granulopoiesis
por: Zhang, Yangyang, et al.
Publicado: (2019)

Ciclesonide/iguratimod: Prolonged presence of SARS-CoV-2: case report
Publicado: (2020)

Influence of Iguratimod on Bone Metabolism in Patients with Rheumatoid Arthritis: A Meta-analysis
por: Deng, Li, et al.
Publicado: (2022)

Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literature
por: Li, Xiao-li, et al.
Publicado: (2018)

Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis
por: Xu, Yunzhi, et al.
Publicado: (2015)

Egr2 and Egr3 are the unique regulators for systemic autoimmunity
por: Sumitomo, Shuji, et al.
Publicado: (2013)

Serum KL‐6 level is a prognostic marker in patients with anti‐MDA5 antibody‐positive dermatomyositis associated with interstitial lung disease
por: Ye, Yan, et al.
Publicado: (2019)

Protease Nexin I is a feedback regulator of EGF/PKC/MAPK/EGR1 signaling in breast cancer cells metastasis and stemness
por: Tang, Tingting, et al.
Publicado: (2019)

Conflict between efficacy and economy in rheumatoid arthritis treatment: Iguratimod is found at a compromise
por: Tanaka, Masao
Publicado: (2021)

Research progress on the clinical application and mechanism of iguratimod in the treatment of autoimmune diseases and rheumatic diseases
por: Long, Zhiyong, et al.
Publicado: (2023)

Clinical Efficacy of Methotrexate Combined with Iguratimod on Patients with Rheumatoid Arthritis and Its Influence on the Expression Levels of HOTAIR in Serum
por: Tan, Jingya, et al.
Publicado: (2021)

Iguratimod suppresses Tfh cell differentiation in primary Sjögren’s syndrome patients through inhibiting Akt/mTOR/STAT3 signaling
por: Lyu, Taibiao, et al.
Publicado: (2023)

Correction: Protease Nexin I is a feedback regulator of EGF/ PKC/MAPK/EGR1 signaling in breast cancer cells metastasis and stemness
por: Tang, Tingting, et al.
Publicado: (2020)

A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia
por: Wang, Shuhua, et al.
Publicado: (2023)

Iguratimod promotes transformation of mononuclear macrophages in elderly patients with rheumatoid arthritis by nuclear factor-κB pathway
por: Liu, Sha, et al.
Publicado: (2021)

Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated
por: Wu, Chunmei, et al.
Publicado: (2019)

Effectiveness and Safety of Iguratimod in Treating Primary Sjögren’s Syndrome: A Systematic Review and Meta-Analysis
por: Pu, Jincheng, et al.
Publicado: (2021)

Iguratimod in treatment of primary Sjögren’s syndrome concomitant with autoimmune hemolytic anemia: A case report
por: Zhang, Juan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nt3qo3pm4bl89db2r3l1vf00n1